Medivir is a pharmaceutical company focusing on the development of innovative treatments for cancer.
Medivir focuses on cancers of high unmet medical need to provide benefit to patients who so far have had few treatment options.Our projects >
Medivir leverages collaborations with academic and industrial partners in order to bring specialty knowledge, experience and other capabilities to our projects.Partnership >
Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACRRead more
First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with LenvimaRead more
Medivir to present at the Stockholm Corporate Finance Life Science DayRead more
Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.